Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-945429 dose-ranging study in moderate to severe Crohn's disease
2011-004763-72Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing BMS-945429 dose-ranging arm(s) with Placebo (2 arms). Started Apr 2012; status: completed.
02
Drugs
clazakizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-004763-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004763-72.